4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line

Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for complicated urinary tract infections, the company and its partner GSK have pushed Utebzi across the finish line.